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Aortic Valve Disease (AVD) is the most common Valvular Heart Disease (VHD), affecting 
millions of people worldwide. Severe AVD is treated in most cases with prosthetic 
aortic valve replacement, which involves the substitution of the native aortic valve with 
a prosthetic one. In this review we will discuss the different types of prosthetic aortic 
valves available for implantation and the challenges faced by patients, medical doctors, 
researchers and manufacturers, as well as the approaches that are taken to overcome 
them.
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intRoduCtion
In Europe alone more than 13 million people (1) are diagnosed with Valvular Heart disease (VHD) 
each year and 100 million worldwide (2). VHD primarily affects the elderly (>65 years old) in western 
countries and young people (<30 years old) in developing countries, because of the high incidence of 
rheumatic heart disease and short life expectancy (3 ESC Guidelines; Supplement).
The deterioration of native heart valves (tricuspid, pulmonary, mitral, aortic) once started is 
difficult to treat or revert with medications, leaving valve replacement as the only option, whenever 
valvuloplasty is not possible (4).
Aortic Valve Disease (AVD) is the most common among valvular conditions (44,3% VHD are AVD) 
(5) and the gold standard treatment was Surgical Aortic Valve Replacement/Implantation (SAVR or 
SAVI) until the introduction in 2007 of a new revolutionary procedure, Transcatheter Aortic Valve 
Replacement/Implantation (TAVR or TAVI). TAVI became especially used in inoperable, i.e., high-
risk patients, as it is les s invasive than an open-heart surgery (6).
Both SAVI and TAVI are not risk-free, tough, in fact, patients are subjected to life threatening 
complications associated with the medications given post-implantation and with the deterioration 
of the implanted valve (7).
In this review we will discuss prosthetic aortic valves, pre and post implantation challenges, and 
their solutions.
Aortic valve disease (Avd)
Aortic Stenosis (AS) accounts for the majority of AVD (almost 50% of all VHD). AS prevalence in 
Europe is 3–8% among people over 75 years old. If untreated, 90% of patients with severe AS have 
a life expectancy of less than 10 years, and 50% of the patients will die in the 2–3 years following 
symptoms onset (3 ESC Guidelines; Supplement).
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Calcific Aortic Stenosis (CAS), which is the formation of 
fibro-calcic nodules on the valve has a prevalence of 0,4% in the 
general population and 1,7% in the population over 65 years old 
(8). The pathophysiology of CAS is complex, it involves lipoprotein 
deposition, inflammation and osteoblast transition of valve 
interstitial cells (Hulin A et al. in this issue).
Risk factors for AS in the general population are the same as 
atherosclerotic vascular diseases, i.e., diabetes, hypercholesterolemia, 
hypertension and tobacco usage (9).
Medication is unable to stop or revert the process of native 
aortic valve degeneration, with solutions limited to reparation/
reconstruction or, in most cases, replacement.
Aortic valve Replacement
Worldwide the number of aortic valve replacement in 2003 was 
290,000 and by 2050 is predicted to be 850,000 (10).
Prosthetic aortic valves can be of 3 different types: (1) Surgical 
Mechanical Aortic Valves in different material, including stainless 
steel, pyrolitic carbon or ceramic, and with different shapes - caged-
ball, monoleaflet and bileaflet. They are structurally robust and can 
theoretically have a long service life (25–30 years). (2) Surgical 
Biological Aortic Valves are made of biological tissue that can be 
xenogenic (bovine or porcine) or allogenic (homograft), stented or 
stentless. Durability is the main problem with these valves, which 
last between 10–15 years. (3) Transcatheter or Percutaneous Aortic 
Valves are tissue heart valves and can be of two types: expanded 
over a balloon or self-expandable. They are inserted percutaneously 
and are easy to implant, but, like surgical bioprosthesis, they are 
not long lasting.
The surgical procedure for aortic valve replacement involves an 
open-heart surgery, the heart is stopped and the patient is attached 
to a bypass to oxygenate the blood. Since SAVI is quite invasive, it 
has been slowly replaced by TAVI, which can have 3 different sites 
of vascular access: transfemoral, subclavian or carotid artery and 
clinical trials are currently ongoing to evaluate the approach that 
will give least complications. TAVI is performed in cases where 
patients are at high risk of death during surgery, due to old age or 
the presence of additional diseases. Two randomized prospective 
clinical trials, PARTNER 1 (Placement of AoRtic TraNscatheER) 
(11) and CoreValve (12) have proven the superiority of TAVI over 
SAVI in a high-risk cohort of patients. Moreover, in July 2017 
- the year of the 15 year anniversary of TAVI (13) - the FDA, 
based on the favorable conclusions of two trials, the PARTNER 2 
(14) and the SURTAVI, has approved the use of TAVI in patients 
with intermediate risk of a negative outcome during open-heart 
surgery. But SAVI still remains the reference method, especially 
in low-risk patients. To be able to extend TAVI to all patients, 
regardless of surgical risk, more studies, focused on the outcomes 
of the procedure in the long run, are needed (15).
Both SAVI and TAVI are associated with thrombosis (2), but it is 
becoming evident that during TAVI there are more periprocedural 
ischemic and embolic strokes, caused by the dislodgement of 
debris from the aortic arch, annulus, and native valve (16). To 
reduce such thromboembolic events, the clinical trial GALILEO 
( clinicaltrials. gov, NCT02556203) is at the moment recruiting 
patients to test the hypothesis that, being thrombin a key-player 
in the pathophysiology of thromboembolic events, patients would 
benefit from treatment with anticoagulants, like rivaroxaban.
Management of Aortic valve Replacement
For an aortic valve replacement medical doctors are faced with 
many decisions, e.g.,: define when the aortic valve condition is severe 
enough to perform the replacement; what kind of intervention - 
SAVI or TAVI - to perform; and what kind of prosthetic aortic valve 
to use - mechanical or biological [(17)  ESC Guidelines]. This is why 
it is very important that a multidisciplinary heart team evaluates 
risks and benefits of all pre and post-procedural decision (18).
Usually, mechanical valves, which are more thrombogenic, but 
more durable, are implanted in patients younger than 65 years old, 
which have good hemodynamics, while biological valves are used 
mainly in the elderly. Although less thrombogenic, tissue valves 
(surgical or trasncatheter) are prone to structural valve deterioration 
(SVD), caused mainly by calcification (19) . Nevertheless, more 
than half of valve replacements are bioprosthetic, especially after 
the introduction of TAVI in 2007.
Since mechanical valves are thrombogenic, they require long-
term vitamin K antagonists (warfarin) and antiplatelet drugs 
(aspirin) administration. However, such treatments may increase 
the risk of bleeding. Bioprosthetic, both surgical and transcatheter, 
valves have better hemodynamic properties compared to mechanical 
ones, therefore, the antithrombotic treatment is just required for the 
first months post-surgery (3–6 months) to reduce thromboembolic 
complications, during the process of prosthesis endothelialization 
(neointimal coverage of the frame and leaflets) (2).
The choice of the best valve to implant depends mainly on 
two risk factors: anticoagulation-related bleeding and valve 
deterioration. Tissue valves are implanted when the risk of bleeding 
with anticoagulation treatment is high, while mechanical valves 
are implanted when valve tissue deterioration could be accelerated, 
i.e., in younger patients.
Antithrombotic management slows down, but does not 
eliminate the risk of prosthetic valve failure, which depends also 
on the life-style of the patient as well as on the pre-procedural 
metabolic profile and inflammatory status, especially for TAVI.
Causes of Failure of Prosthetic valves
Prosthetic valve dysfunction depends on the valve that has been 
implanted and on the procedure (SAVI or TAVI). Atherosclerosis 
risk factors, like diabetes, smoking, hypercholesterolemia, 
metabolic syndrome may accelerate failure of prosthesis, while 
dental procedures and other surgeries may increase the risk of 
valve infection.
Infection
The risk of infection of the prosthetic aortic valve is much higher 
compared to native valves and can affect all types of prosthesis 
equally, leading to infective endocarditis. Infections can arise just after 
surgery (within a week to one month post-surgery), or appear long 
after surgery (after 6 months). Periprocedural and 30 days infections 
are more common during SAVI compared to TAVI, although such 
differences are not statistically significant (7).
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Since bacteria colonization of prosthetic valves and, of biomedical 
devices in general, is difficult to fight, because of biofilm formation 
(bacteria in the biofilm are more resistant to the usual antibiotics 
doses), it is important to prevent infections that can arise during 
dental procedures or other surgeries, with the use of antibiotics [(20) 
ESC Guidelines].
Thrombosis
Altered local flow due to the presence of prosthetic valve may be a 
trigger for thrombosis. In fact, high shear stress levels could potentially 
damage red blood cells (hemolysis) and activate platelets, promoting 
thrombogenesis.
The disruption of the normal local flow can also be caused by 
implantation errors e.g., when the transplanted valve does not have the 
right geometry/model, with a specific annulus size, different for each 
patient. We talk in this case of a Patient-Prosthesis Mismatch (PPM). 
To prevent PPM cases, medical doctors should use fluid dynamic 
computational simulations before valve implantation.
While bioprosthesis are the least thrombogenic, mechanical 
and transcatheter valves are comparable in terms of thrombogenic 
potential, due to their similar transvalvular flow gradients (21).
Another important mechanism leading to thrombosis is surface–
induced thrombosis, which has been well described in mechanical 
valves and other medical devices. The contact of prosthetic valves with 
blood (biomaterial-blood interaction) triggers a thrombogenic process 
that involves: (1) adhesion of platelets via surface-adsorbed plasma 
proteins, like lipoproteins, fibrinogen, fibronectin, von Willebrand 
factor (VWF) or laminin. (2) Activation of the “Contact Activation 
Coagulation System” via negatively charged surfaces activating Factor 
XII (FXII). (3) Activation of the “Extrinsic Coagulation System” via 
adhered microparticles containing Tissue Factor (TF), released by 
several activated cellular components, like activated leukocytes. (4) 
Adhesion of leukocytes, in particular neutrophils and neutrophil 
extracellular traps (NETs), leading to inflammatory reactions, 
which promote platelet capture and aggregation. (5) Activation 
of complement via FXII, which further amplifies the coagulation 
cascade. All these events result in thrombin generation, activation of 
platelets and formation of platelets-fibrin networks on the prosthetic 
surface. The fate of such thrombus would be to obstruct blood flow in 
the place that it was generated or to detach and enter the circulation. 
To counteract thrombus formation, macrophages can infiltrate 
the thrombus for the clearance of NETs and provide plasminogen 
activator, important for fibrinolytic processes (22).
With the more frequent use of transcatheter aortic valves it is 
becoming important to understand the pathological processes and 
the triggering mechanisms associated with thrombosis of such valves. 
In fact, thrombo-embolic events have been reported in TAVI patients 
especially in the first 3 months post-procedure. One hypothesis is 
that, since the native valve is not removed, but left in place during 
TAVI, the leaflets of the stenotic native valve are still rich in TF, which 
exacerbates platelet activation (2).
Calcification
Calcification occurs more on bioprosthetic valves than on mechanical 
valves. Bioprosthesis are made of glutaraldehyde-fixed porcine valve 
cusps or bovine pericardium, composed of devitalized cells valvular 
interstitial cells (VICs) or fibroblast from porcine or bovine tissues, 
respectively, embedded in an extracellular matrix of collagen, elastin, 
and glycosaminoglycans (GAGs). Glutaraldehyde is the primary 
cause of calcification (23). Although the pathophysiology of valve 
mineralization is poorly understood, collagen and elastin fibers can 
serve as nucleation sites for calcium phosphate minerals. Moreover, 
calcium phosphate minerals have also been observed at the membrane 
of devitalized VICs (24). The mechanism of formation of calcium 
deposits in devitalized cells is probably due to calcium influx from the 
surrounding area of the cells to the inside of cells. The consequence 
is the formation of hydroxyapatite by reaction of such Ca2+ with free 
phosphate groups derived from membrane’s phospholipids.
Procoagulant actors, such as phosphatidylserine-exposing 
activated platelets and TF-expressing immune cells or microparticles, 
lipid accumulation and inflammation may also play a role in 
calcification. However, the relationship between bioprosthesis 
calcification, lipids, inflammation, and thrombosis has never been 
established. Whether thrombosis promotes calcification, and/or vice 
versa is unknown.
outcomes: Challenges and Solutions
Considering all complications of prosthetic aortic valves, there is an 
urgent need to improve their design, biocompatibility and durability 
(25).
The development of a prosthetic aortic valve is a very complex 
matter, achieved with teams of chemists, bioengineers and medical 
doctors. A prosthetic aortic valve to be clinically safe and durable 
has to comply to many regulations, pass extensive in vitro testing, 
preclinical studies in animal models (pig or sheep) (Table 1) and 
clinical trials (26).
Biocompatibility and haemocompatibility of the material of the 
valves is crucial and has to follow the ISO 10993 guidelines. The in 
vitro tests should evaluate the effect of the prolonged contact of the 
prosthetic valve surface with whole blood at 37°C under shear stress. 
Lysis of red blood cells can be measured using Lactate Dehydrogenase 
(LDH) activity, while flow-induced platelet activation can be studied 
in a perfusion chamber or in a cone and plate device.
An important parameter to determine is the clotting time of plasma 
that has been in contact with the biomaterial. Such test, if performed 
using specific inhibitors, allows the discrimination between intrinsic 
and extrinsic pathways of coagulation, which is important if we want 
improve prosthetic valve surfaces. Other important tests are cell 
toxicity as well as immunogenicity of the biomaterial of the valves. 
The latter evaluated is a measurement of complement (C5a and C3a) 
activation.
Anti-fouling properties refer to capacity of the material repulse 
bacteria or other microorganisms. With an anti-fouling biomaterial, 
microorganisms are not able to adhere and form biofilms of the surface 
tABLe 1 |  In vitro and in vivo tests in prosthetic aortic valve development.
Biocompatibility iSo 10993 tests
Infection Anti-fouling tests (ISO 14160)
Hemodynamics Pulse Duplicator (ISO 5840)
Durability Durability Testers + Shelf life testing (ISO 5840–
1 Annex G, H, I, J)
Calcification In vivo animal models 20 weeks (ISO 5840–2)
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of the implanted prosthesis. Biomaterials with anti-fouling properties 
would avoid colonization and accumulation of microorganisms on 
the surface of the valve (27). Examples of anti-fouling surfaces are 
poly(ethylene glycol) PEG, oligo(ethylene glycol) or zwitteronic 
species (28).
Geometry/Design of prosthetic aortic valves is of crucial 
importance to retain similar hemodynamic properties of native 
valves. Despite years of studies on the geometrical design of 
mechanical valves, the super-physiological shear stresses leading to 
valve deterioration, thrombosis and to a lesser extend calcification, 
are still detected with this kind of valves. Usually, hemodynamics of 
prosthetic valves are first tested in silico, using numerical simulations, 
like 2D computational fluid dynamic (CFD) or, more recently, 
3D fluid-structure interaction (FSI) simulations. Hydrodynamic 
performance of a prosthetic valve is then evaluated in vitro using a 
Pulse Duplicator (ISO 5840:2005).
Durability is a critical issue, especially with bioprosthetic 
valves. An ideal bioprosthetic valve should be like a native 
valve, extremely durable, going through 40 million cycles a 
year and 3 billion during a life-time. In native valves durability 
and strength is given by the flexibility and heterogeneity of the 
supportive structures (collagen, connective tissue and elastin) 
and cells (Valvular Endothelial, VECs, and Interstitial cells, 
VICs). Bioprosthetic valves are far from having similar durability, 
making this issue an important point to improve for the next 
generation of bioprosthetic valves. Durability or prolonged 
accelerated wear testing is mandatory. Prosthesis durability 
testers can simulate 10 years of valve usage in 6 months.
Sterility is fundamental for implantable medical devices. Sterility is 
evaluated using the Sterility Assurance Level (SAL), which represents 
the probability of a single viable microorganism occurring on an 
item after sterilization. While this probability can be reduced to a 
very low number, it can never be reduced to zero. Accepted SAL 
values are 10−3 and 10−6 for non-implantable device and implantable 
device respectively. The methods used to sterilize are ethylene 
oxide, radiation (gamma rays), ozone or addition of antibiotics. It 
is important to choose the right sterilization method, as it can affect 
SVD.
ConCLuSionS And FutuRe 
PeRSPeCtive
Although extensive in vitro and in vivo testing is done prior to releasing 
a prosthetic valve on the market, prosthetic valve thrombosis, as well 
as infection and calcification, cannot be avoided.
Several solutions have been proposed to mitigate calcification, like 
chemical anticalcification agents like deritatives of ammino oleic acid 
(AOA). Such delipidating agent has been proven effective in removing 
membrane-bound phospholipids derived from devitalized cells and 
in reducing calcification (29).
Moreover, alternatives to glutaraldehyde fixation, which is the most 
used cross-linking agent, have also been proposed (dye-mediated 
photofication,carbodiimide-based fixation). In fact, glutaraldehyde 
residues in the bioprosthesis have been implicated in calcification 
and lack of endothelization (29).
Prevention of prosthesis failure could be achieved with the new 
generation of smart heart devices, capable of auto-detecting their 
status or by measuring specific markers in plasma that could predict 
prosthetic valve failure. For bioprosthesis, for example, several markers 
have been identified as predictors of SVD: the ratio apolipoprotein B 
and A-I (apoB/apoA-I) (30); Lipoprotein-associated phospholipase 
A2 (Lp-PLA) (31); and the ratio of oxidized low-density lipoprotein 
and high-density lipoprotein (OxLDL/HDL) and proprotein 
convertase subtilisin/kexin 9 (PCSK9) levels (32).
Lots of hopes lie in Heart Valve Tissue Engineering (HVTE), 
involving in vitro coating of a matrix with appropriate cell types. 
The matrix can be biodegradable or not and the cell types can 
be stem or progenitor cells, autologous or allogenic (10). The 
idea is to develop heart valve substitutes containing living cells 
able to actively respond and adapt to surrounding mechanical 
stresses, mimicking more closely the complex functions of native 
valves (33, 34).
Another alternative is Polymeric Heart Valves (PHV), primarily 
made of polyurethane (PU-PHV) (35). The geometry of such 
valves is better controlled (trileaflets) for optimal durability and 
hemodynamics. Since PU-PHVs are not made of animal tissue, they 
are safer and less expensive and could be used in TAVI, due to their 
flexibility. On the other hand, the creation of a flexible polymeric 
material that can withstand aortic valve flows has proven challenging 
and resulted in many failures.
To solve geometry issues, like PPM, the latest technologies use 
stereolithographic 3D printing of models based on X-ray computer 
tomography (CT) scans of native valves (36). Using this technology 
it becomes possible to produce a tailor-made prosthetic valve, made 
of tissue or polymers that would mimic closely the native valve with 
a minimal impact.
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